Skip to main content
SpringerLink
Log in

Head and Neck Tumors

  • Chapter
  • First Online:
Positron Emission Tomography

  • 2466 Accesses

Abstract

According to statistics, every year more than 35,000 cases of planocellular cancer of the head and neck are registered (Forastiere et al. 2001). Head and neck cancers make up about 5% of the total number of tumors, planocellular cancer being the widest-spread histological subtype. Smoking and other ways of consuming tobacco as well as alcohol consumption increase the risk of developing this kind of cancer. Planocellular cancer of the head and neck (PCHN) has specific development stages for every anatomic region in the larynx, buccal cavity, oropharynx, hypopharynx, nasopharynx and paranasal sinuses. More than 50% cases of this kind of cancer appear in the oropharynx, especially on the palatine tonsils and at the base of tongue. Currently about 60% PCHN patients have developed local manifestations and undergo treatment with surgical intervention, radiotherapy, chemotherapy or a combination of these kinds of treatment (Forastiere and Urba 1995; Forastiere 1994).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Suggested Reading

  • Boerner AR, Petrich T, Weckesser E et al (2002) Monitoring isotretinoin therapy in thyroid cancer using 18F-FDG-PET. Eur J Nucl Med Mol Imaging 29:231–236

    Article  PubMed  CAS  Google Scholar 

References

  • AACE Clinical Practice Guidelines for the Management of Thyroid Carcinoma (2001)

    Google Scholar 

  • Ali S, Tiwari R, Snow G (1985) False positive and false negative neck nodes. Head Neck 8:78–82

    Article  CAS  Google Scholar 

  • Alnafisi NS, Driedger AA, Coates G et al (2000) FDG-PET of recurrent or metastatic 131I-negative papillary thyroid carcinoma. J Nucl Med 41:1010–1015

    PubMed  CAS  Google Scholar 

  • Bhattacharyya N, Nayak VK (2005) Survival outcomes for second primary head and neck cancer: a matched analysis. Otolaryngol Head Neck Surg 132:63–68

    Article  PubMed  Google Scholar 

  • Bobbins RJ, Tuttle RM, Sharaf RN et al (2001) Preparation by recombinant human thyrotropin or thyroid hormone withdrawal are comparable for the detection of residual differentiated thyroid carcinoma. J Clin Endocrinol Metab 86:619–625

    Article  Google Scholar 

  • Bockisch A, Brandt-Mainz K, Gorges R et al (2003) Diagnosis in medullary thyroid cancer with [18F]FDG-PET and improvement using a combined PET/CT scanner. Acta Med Austriaca 30:22–25

    Article  PubMed  CAS  Google Scholar 

  • Braams JW, Pruim J, Freiling NJ et al (1995) Detection of lymph node metastates of squamous cell cancer of the head and neck with FDG-PET and MRI. J Nucl Med 36:211–216

    PubMed  CAS  Google Scholar 

  • Chen YK, Liu FY, Yen RF, Kao CH (2003) Compare FDG-PET and Tc-99m tetrofosmin SPECT to detect metastatic thyroid carcinoma. Acad Radiol 10:835–839

    Article  PubMed  Google Scholar 

  • Chung JK, Park YJ, Kim TY et al (2002) Clinical significance of elevated level of serum ­antithyroglobulin antibody in patients with differentiated thyroid cancer after thyroid ablation. Clin Endocrinol 57:215–221

    Article  Google Scholar 

  • Collins BT, Gardner LJ, Verma AK et al (1998) Correlation of fine needle aspiration biopsy and fluoride-18 fluorodeoxyglucose positron emission tomography in the assessment of locally recurrent and metastatic head and neck neoplasia. Acta Cytol 42:1325–1329

    Article  PubMed  CAS  Google Scholar 

  • Diehl M, Risse JH, Brandt-Mainz K et al (2001) Fluorine-18 fluorodeoxyglucose positron emission tomography in medullary thyroid cancer: results of a multicentre study. Eur J Nucl Med 28:1671–1676

    Article  PubMed  CAS  Google Scholar 

  • Fatourechi V, Hay ID, Mullan BP et al (2000) Are post-therapy radioiodine scans informative and do they influence subsequent therapy of patients with differentiated thyroid cancer? Thyroid 10:573–577

    Article  PubMed  CAS  Google Scholar 

  • Forastiere AA (1994) Overview of platinum chemotherapy in head and neck cancer. Semin Oncol 21:20–27

    PubMed  CAS  Google Scholar 

  • Forastiere AA, Urba SG (1995) Experimental therapeutic approaches for recurrent head and neck cancer. Cancer Treat Res 4:263–281

    Article  Google Scholar 

  • Forastiere A, Koch W, Trotti A, Sidransky D (2001) Head and neck cancer. NEJM 345:1890–1900

    Article  PubMed  CAS  Google Scholar 

  • Freudenberg et al (2004) Value of (124)I-PET/CT in staging of patients with differentiated thyroid cancer

    Article  PubMed  CAS  Google Scholar 

  • Frilling A, Tecklenborg K, Gorges R et al (2001) Preoperative diagnostic value of [(18)F]fluorodeoxyglucose positron emission tomography in patients with radioiodine-negative recurrent well-differentiated thyroid carcinoma. Ann Surg 234:804–811

    Article  PubMed  CAS  Google Scholar 

  • Goerres GW, Schmid DT, Gratz KW et al (2003) Impact of whole body positron emission tomography on initial staging and therapy in patients with squamous cell carcinoma of the oral cavity. Oral Oncol 39:547–551

    Article  PubMed  CAS  Google Scholar 

  • Goshen E, Cohen O, Rotenberg G et al (2003) The clinical impact of 18F-FDG gamma PET in patients with recurrent well differentiated thyroid carcinoma. Nucl Med Commun 24:959–961

    Article  PubMed  CAS  Google Scholar 

  • Grunwald F, Menzel C, Bender H et al (1998) Redifferentiation therapy-induced radioiodine uptake in thyroid cancer. J Nucl Med 39:1903–1906

    PubMed  CAS  Google Scholar 

  • Grunwald F, Kalicke T, Feine U et al (1999) Fluorine-18 fluorodeoxyglucose positron emission tomography in thyroid cancer: results of a multicentre study. Eur J Nucl Med 26:1547–1552

    Article  PubMed  CAS  Google Scholar 

  • Hung MC, Wu HS, Kao CH et al (2003) F18-fluorodeoxyglucose positron emission tomography in detecting metastatic papillary thyroid carcinoma with elevated human serum thyroglobulin levels but negative I-131 whole body scan. Endocr Res 29:169–175

    Article  PubMed  Google Scholar 

  • Jemal et al (2007) Cancer statistic. CA Cancer J Clin : 57:43–66

    Article  PubMed  CAS  Google Scholar 

  • Jungehulsing M, Scheidhauer K, Damm M et al (2000) 2[F]-fluoro-2-deoxy-D-glucose positron emission tomography is a sensitive tool for the detection of occult primary cancer (carcinoma of unknown primary syndrome) with head and neck lymph node manifestation. Otolaryngol Head Neck Surg 123:294–301

    Article  PubMed  CAS  Google Scholar 

  • Khan N, Oriuchi N, Higuchi T et al (2003) PET in the follow-up of differentiated thyroid cancer. Br J Radiol 76:690–695

    Article  PubMed  CAS  Google Scholar 

  • Kole AC, Nieweg OE, Pruim J et al (1998) Detection of unknown occult primary tumors using positron emission tomography. Cancer 82:160–166

    Article  Google Scholar 

  • Kubicek et al (2010) FDG-PET staging and importance of lymph node SUV in head and neck cancer. Head & Neck Oncology 2:19

    Article  Google Scholar 

  • Larson SM, Robbins R (2002) Positron emission tomography in thyroid cancer management. Semin Roentgenol 37:169–174

    Article  PubMed  Google Scholar 

  • Lind P, Kresnik E, Kumnig G et al (2003) 18F-FDG-PET in the follow-up of thyroid cancer. Acta Med Austriaca 30:17–21

    Article  PubMed  CAS  Google Scholar 

  • Lowe VJ, Mullan BP, Hay ID et al (2003) 18F-FDG-PET of patients with Hurthle cell carcinoma. J Nucl Med 44:1402–1406

    PubMed  Google Scholar 

  • Macapinlac HA (2001) Clinical usefulness of FDG-PET in differentiated thyroid cancer. J Nucl Med 42:77–78

    PubMed  CAS  Google Scholar 

  • Menzel C, Zaplatnikov K, Diehl M et al (2004) The influence of thyroglobulin on functional imaging in differentiated thyroid cancer. Nucl Med Commun 25:239–243

    Article  PubMed  CAS  Google Scholar 

  • Mettler FA, Guiberteau MJ (1998) Essentials of nuclear medicine imaging, 4th edn. WB Saunders, Philadelphia, p 120

    Google Scholar 

  • Pacini F, Agate L, Elisei R et al (2001) Outcome of differentiated thyroid cancer with detectable serum Tg and negative diagnostic (131)I whole body scan: comparison of patients treated with high (131)I activities versus untreated patients. J Clin Endocrinol Metab 86:4092–4097

    Article  PubMed  CAS  Google Scholar 

  • Palmedo et al. (2006) Integrated PET/CT in differentiated thyroid cancer: diagnostic accurancy and impact on patient management. J Nucl Med 47(4): 616–624.

    Google Scholar 

  • Petrich T, Borner AR, Weckesser E et al (2001) Follow-up of differentiated thyroid cancer patients using rhTSH – preliminary results. Nuklearmedizin 40:7–14

    PubMed  CAS  Google Scholar 

  • Petrich T, Borner AR, Otto D et al (2002) Influence of rhTSH on [(18)F]fluorodeoxyglucose uptake by differentiated thyroid carcinoma. Eur J Nucl Med Mol Imaging 29:641–647

    Article  PubMed  CAS  Google Scholar 

  • Pineda J, Lee T, Ain K et al (1995) Iodine-131 therapy for thyroid cancer patients with elevated thyroglobulin and negative diagnostic scan. J Clin Endocrinol Metab 80:1488–1492

    Article  PubMed  CAS  Google Scholar 

  • Plotkin M, Hautzel H, Krause BJ et al (2002) Implication of 2-18fluor-2-deoxyglucose positron emission tomography in the follow-up of Hurthle cell thyroid cancer. Thyroid 12:155–161

    Article  PubMed  Google Scholar 

  • Reske S et al Results of the 3rd German Interdisciplinary Consensus Conference, “Onko PET III”, 21 July and 19 September 2000. EJNM 28/11 (2001): 1707–1723

    Google Scholar 

  • Robbins RJ, Hill RH, Wang W et al (2000) Inhibition of metabolic activity in papillary thyroid carcinoma by a somatostatin analogue. Thyroid 10:177–183

    Article  PubMed  CAS  Google Scholar 

  • Robbins R, Drucker W, Hann L et al (2001) Advances in the detection of residual thyroid carcinoma. Adv Intern Med 46:277–294

    PubMed  CAS  Google Scholar 

  • Schluter B, Bohuslavizki KH, Beyer W et al (2001) Impact of FDG-PET on patients with differentiated thyroid cancer who present with elevated thyrogiobulin and negative 131I scan. J Nucl Med 42:71–76

    PubMed  CAS  Google Scholar 

  • Schoeder H, Yeung H, Gonen M, Kraus D, Larson S (2004) Head and Neck Cancer: Clinical Usefullness and Accuracy of PET/CT Image Fusion. Radiology 231:65–72.

    Article  Google Scholar 

  • Stern WB, Silver CE, Zeifer BA et al (1990) Computed tomography of the clinically negative neck. Head Neck 12:109–113

    Article  PubMed  CAS  Google Scholar 

  • Stokkel MP, ten Brock FW, van Rijk PP (1998) The role of FDG PET in the clinical management of head and neck cancer. Oral Oncol 34:466–471

    Article  PubMed  CAS  Google Scholar 

  • Van den Bruel A, Maes A, De Potter T et al (2002) Clinical relevance of thyroid fluorodeoxyglucose-whole body positron emission tomography incidentaloma. J Clin Endocrinol Metab 87:1517–1520

    Article  PubMed  Google Scholar 

  • Van Tol KM, Jager PL, Dullaart RP et al (2000) Follow-up in patients with differentiated thyroid carcinoma with positive 18F-fluoro-2-deoxy-D-glucose-positron emission tomography results, elevated thyroglobulin levels, and negative high-dose 131I posttreatment whole body scans. J Clin Endocrinol Metab 85:2082–2083

    Article  PubMed  Google Scholar 

  • Van Tol KM, Jager PL, Piers DA et al (2002) Better yield of (18)fluorodeoxyglucose-positron emission tomography in patients with metastatic differentiated thyroid carcinoma during thyrotropin stimulation. Thyroid 12:381–387

    Article  PubMed  Google Scholar 

  • Van Tol KM, Jager PL, de Vries EG et al (2003) Outcome in patients with differentiated thyroid cancer with negative diagnostic whole-body scanning and detectable stimulated thyroglobulin. Eur J Endocrinol 148:589–596

    Article  PubMed  Google Scholar 

  • Vokes EE, Weichselbaum RR, Lippman SM et al (1993) Head and neck cancer. N Engl J Med 328:184–194

    Article  PubMed  CAS  Google Scholar 

  • Wang W, Macapinlac H, Larson SM et al (1999) 18FJ-2- fluoro-2-deoxy-D-glucose positron emission tomography localizes residual thyroid cancer in patients with negative diagnostic (131)I whole body scans and elevated serum thyroglobulin levels. J Clin Endocrinol Metab 84:2291–2302

    Article  PubMed  CAS  Google Scholar 

  • Wang W, Larson SM, Fazzari M et al (2000) Prognostic value of [18F]fluorodeoxyglucose positron emission tomographic scanning in patients with thyroid cancer. J Clin Endocrinol Metab 85:1107–1113

    Article  PubMed  CAS  Google Scholar 

  • Wang W, Larson SM, Tuttle RM et al (2001) Resistance of [18f]-fluorodeoxyglucose-avid metastatic thyroid cancer lesions to treatment with high-dose radioactive iodine. Thyroid 11:1169–1175

    Article  PubMed  CAS  Google Scholar 

  • Wax MK, Myers LL, Gabalski EC et al (2002) Positron emission tomography in the evaluation of synchronous lung lesions in patients with untreated head and neck cancer. Arch Otolaryngol Head Neck Surg 128:703–707

    PubMed  Google Scholar 

  • Welsch M, Abeln M, Zaplatnikov K et al (2007) Multiparameter scoring system for the prognosis of differentiated thyroid cancer. Nuklearmedizin 46:257–262

    PubMed  CAS  Google Scholar 

  • Wunderlich G, Zophel K, Crook L et al (2001) A high-sensitivity enzyme-linked immunosorbent assay for serum thyroglobulin. Thyroid 11:819–824

    Article  PubMed  CAS  Google Scholar 

  • Zhuang H, Kumar R, Mandel S, Alavi A (2004) Investigation of thyroid, head, and neck cancers with PET. Radiol Clin North Am 42:1101–1111

    Article  PubMed  Google Scholar 

  • Zimmer LA, McCook B, Meltzer C et al (2003) Combined positron emission tomography/computed tomography imaging of recurrent thyroid cancer. Otolaryngol Head Neck Surg 128:178–184

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Russian Research Center for Radiology and Surgery, St. Petersburg, Russia

    Anatoliy Granov

  2. Department of Radiology and Nuclear Medicine, Russian Research Center for Radiology, St. Petersburg, Russia

    Leonid Tiutin

  3. Department of Nuclear Medicine Division of Radiology, Medical University Graz, Graz, Austria

    Thomas Schwarz M.D.

Authors
  1. Anatoliy Granov
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Leonid Tiutin
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Thomas Schwarz M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Russian Research Center for Radiology an, Pesochny, ul. Leningradskaya 70, St. Petersburg, 197758, Russia

    Anatoliy Granov

  2. , Dept. of Radiology and Nuclear Medicine, Russian Research Center for Radiology, Pesochny, ul. Leningradskaya 70, St. Petersburg, 197758, Russia

    Leonid Tiutin

  3. , Klinische Abt. für Nuklearmedizin, Universitätsklinik für Radiologie, Auenbruggerplatz 9, Graz, Austria

    Thomas Schwarz

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Granov, A., Tiutin, L., Schwarz, T. (2013). Head and Neck Tumors. In: Granov, A., Tiutin, L., Schwarz, T. (eds) Positron Emission Tomography. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-21120-1_3

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-21120-1_3

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-21119-5

  • Online ISBN: 978-3-642-21120-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation